drugset / Trial / NCT00877890

A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)

NCT00877890

Phase 3 Completed 254 enrolled AstraZeneca Eli Lilly and Company · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will compare the effects of commercially manufactured exenatide once weekly and exenatide BID in subjects whose type 2 diabetes is managed with diet and exercise alone or with oral antidiabetic medications. The study will examine glycemic control (as measured by HbA1C), safety, and tolerability.

Timeline

Start
2009-03
Primary completion
2009-10
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 10 ug
Subject Exenatide Peptide 2 mg